Antineoplastic Drugs in Elderly Patients

Shandong University

Status: Enrolling

Conditions: Cancer

Treatments: Drug: Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)

Study type: Observational

Funder types: Other

Identifiers

NCT05467189

Elderly-Antineoplastic drugs

Details and patient eligibility

About

The purpose is to study the population pharmacokinetics, effectiveness and safety of antineoplastic drugs (Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib, Imatinib, Lapatinib, etc) in elderly patients and recommend optimized dosage regimens.

Enrollment: 500 estimated patients

Sex: All

Ages: 65 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Subjects must meet all of the following inclusion criteria to be enrolled in the study:

1. Age ≥65 years old;
2. Diagnosed with cancer;
3. Using antineoplastic drugs for treatment.

Exclusion criteria

Subjects with any of the following criteria will not be enrolled in this study:

1. Patients who are expected to die within 48 hours;
2. Patients with allergy to antineoplastic drugs;
3. Patients receiving other investigational drugs;
4. Other factors that the researcher considers unsuitable for inclusion.

Trial design

500 participants in 1 patient group

treatment

Description:

The use of antineoplastic agents depends on the clinical practice.

Treatment:

Drug: Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)